Variant · Expression
ABCB1 Overexpression
CI-VAR-00003199Explore in graph →CIViC 2915
Curated evidence
Evidence by cancer (4 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 18191450
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Chronic Myeloid Leukemia, BCR-ABL1 Positive1 | ||||||||
| ABCB1 Overexpression | Bafetinib + DasatinibSubstitutes | Predictive | D | Supports Resistance | 3 | accepted | EID2681The BCR-ABL1 expressing imatinib-resistant cell line K562/D1-9 overexpresses P-glycoprotein (ABCB1), a known drug membrane transporter. Bafetinib (INNO-406) and dasatinib showed drastically higher IC5… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC | civic |
| Lung Adenocarcinoma2 | ||||||||
| EML4::ALK Fusion AND ABCB1 Overexpression | Alectinib + LorlatinibSubstitutes | Predictive | D | Does Not Support Resistance | 3 | accepted | EID10016 | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available
No ClinVar interpretation attached to this variant.